Pine Valley Investments Ltd Liability Co Grows Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Pine Valley Investments Ltd Liability Co lifted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report) by 18.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,449 shares of the biopharmaceutical company’s stock after purchasing an additional 536 shares during the quarter. Pine Valley Investments Ltd Liability Co’s holdings in Regeneron Pharmaceuticals were worth $3,029,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Annis Gardner Whiting Capital Advisors LLC purchased a new position in Regeneron Pharmaceuticals in the third quarter worth $26,000. Fortitude Family Office LLC purchased a new position in Regeneron Pharmaceuticals in the fourth quarter worth $31,000. MCF Advisors LLC raised its position in Regeneron Pharmaceuticals by 50.0% in the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 12 shares in the last quarter. Criterion Capital Advisors LLC purchased a new position in Regeneron Pharmaceuticals in the fourth quarter worth $37,000. Finally, Sutton Wealth Advisors Inc. raised its position in Regeneron Pharmaceuticals by 38.2% in the third quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 13 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on REGN shares. TD Cowen increased their price objective on Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. Bank of America increased their price objective on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a research report on Friday, April 12th. Evercore ISI began coverage on Regeneron Pharmaceuticals in a research report on Tuesday, May 14th. They issued an “outperform” rating and a $1,150.00 price target for the company. Truist Financial restated a “buy” rating and issued a $1,135.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, April 3rd. Finally, UBS Group raised their price target on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a “buy” rating in a research report on Wednesday, April 17th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $989.36.

Check Out Our Latest Analysis on REGN

Regeneron Pharmaceuticals Trading Down 1.1 %

Shares of Regeneron Pharmaceuticals stock traded down $10.55 during trading hours on Wednesday, reaching $962.61. The stock had a trading volume of 28,847 shares, compared to its average volume of 472,181. The firm has a 50 day simple moving average of $945.50 and a two-hundred day simple moving average of $918.05. The firm has a market capitalization of $106.07 billion, a price-to-earnings ratio of 28.75, a P/E/G ratio of 2.03 and a beta of 0.17. The company has a current ratio of 5.27, a quick ratio of 4.51 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals, Inc. has a 1 year low of $684.80 and a 1 year high of $998.33.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Free Report) last announced its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 EPS for the quarter, missing the consensus estimate of $8.46 by ($0.49). The company had revenue of $3.15 billion for the quarter, compared to analysts’ expectations of $3.19 billion. Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. As a group, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.34 earnings per share for the current year.

Insider Activity at Regeneron Pharmaceuticals

In related news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $982.05, for a total transaction of $98,205.00. Following the sale, the director now directly owns 18,282 shares in the company, valued at approximately $17,953,838.10. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $982.05, for a total transaction of $98,205.00. Following the sale, the director now directly owns 18,282 shares in the company, valued at approximately $17,953,838.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Marion Mccourt sold 358 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $967.50, for a total value of $346,365.00. Following the sale, the executive vice president now owns 13,431 shares in the company, valued at $12,994,492.50. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 54,071 shares of company stock worth $52,812,907. 7.48% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Company Profile

(Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

See Also

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.